Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosamprenavir +/- Ritonavir with Zidovudine-containing Regimen in ART-Naive HIV
NCT00043888Phase 3Completed
- Sponsor
- GSK
- Start
- Jan 2002
- Primary completion
- May 2003
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of fosamprenavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by GSK. Primary endpoint: Overall short term tolerance of the regimens at 24 weeks. Started Jan 2002; status: completed.
02
Drugs
fosamprenavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00043888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00043888.